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Abstract
Introduction: Multiple sclerosis (MS) is a chronic, inflammatory, demyelinating disease of the central nervous
system (CNS) in which macrophages play a central role. Initially, macrophages where thought to be merely
detrimental in MS, however, recent evidence suggests that their functional phenotype is altered following myelin
phagocytosis. Macrophages that have phagocytosed myelin may be less inflammatory and may exert beneficial
effects. The presence of myelin-containing macrophages in CNS-draining lymph nodes and perivascular spaces of
MS patients suggests that these cells are ideally positioned to exert an immune regulatory role. Therefore we
evaluated in this study the effect of myelin-phagocytosing macrophages on lymphocyte reactivity.
Methods: Thioglycolate-elicited rat peritoneal macrophages were loaded with myelin and cocultured with myelin-
basic protein (MBP) or ovalbumin (OVA) reactive lymphocytes. Lymphocyte proliferation was determined by CFSE-
labeling. The role of nitric oxide in regulating lymphocyte proliferation was assessed by addition of an inhibitor of
inducible nitric oxide synthase to the coculture. In vivo immune regulation was investigated by treating MBP- and
OVA-immunized animals subcutaneously with myelin. Cognate antigen specific lymphocyte proliferation and nitric
oxide production were determined 9d post-immunization.
Results: In this study we demonstrate that myelin-phagocytosing macrophages inhibit TCR-triggered lymphocyte
proliferation in an antigen-independent manner. The observed immune suppression is mediated by an increase in
NO production by myelin-phagocytosing macrophages upon contact with lymphocytes. Additionally, myelin
delivery to primarily CD169
+ macrophages in popliteal lymph nodes of OVA-immunized animals results in a
reduced cognate antigen specific proliferation. In contrast to OVA-immunized animals, lymphocytes from MBP-
immunized animals displayed an increased proliferation after stimulation with their cognate antigen, indicating that
myelin-phagocytosing macrophages have dual effects depending on the specificity of surrounding lymphocytes.
Conclusions: Collectively our data show that myelin phagocytosis leads to an altered macrophage function that
inhibits lymphocyte proliferation. Additionally, results from this study indicate that myelin-phagocytosing
macrophages fulfill a dual role in vivo. On one hand they aggravate autoimmunity by activating myelin-reactive
lymphocytes and on the other hand they suppress lymphocyte reactivity by producing NO.
Introduction
Multiple Sclerosis (MS) is characterized as a chronic,
inflammatory, neurodegenerative disease of the central
n e r v o u ss y s t e m( C N S ) .I ti sr e g a r d e dt ob ea na u t o i m -
mune disease as activated autoimmune lymphocytes are
pivotal in orchestrating the immunopathological pro-
cesses involved in myelin sheath damage [1-4].
Pathologically, MS is characterized by CNS infiltration
of activated myelin-reactive lymphocytes and
macrophages, resulting in an inflammatory microenvir-
onment. Microglia and macrophages typically accumu-
late in the perivascular spaces and the brain
parenchyma near terminal ovoids of transected axons
[5]. They are thought to be the primary effector cells in
MS and its animal model, experimental allergic ence-
phalomyelitis (EAE) [6-8]. Effector mechanisms of acti-
vated macrophages and microglia include the
internalization of myelin, and the secretion of inflamma-
tory and toxic mediators which negatively influence axo-
nal and myelin integrity [9-22]. * Correspondence: Jerome.hendriks@uhasselt.be
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increasing evidence suggests an additional neuroprotec-
tive role for macrophages. Although two seemingly
mutually exclusive processes, various studies have
reported such a dual role of monocytes and macro-
phages in both injury and repair [23,24]. In neurodegen-
erative models, remyelination is for instance often
correlated with large numbers of macrophages and
microglia in an inflammatory microenvironment [25-27].
Furthermore, as contact with CNS myelin debris inhibits
oligodendrocyte progenitor maturation in vitro,a n da s
macrophages have been described to actively phagocy-
tose myelin debris, local clearance of myelin debris in
the centre or vicinity of lesions is suggested to be a
necessary prerequisite for axonal remyelination follow-
ing demyelination [28]. This hypothesis is supported by
the fact that monocyte depletion and a consequent
inability to clear the microenvironment of myelin debris,
causes an impairment of oligodendrocyte progenitor dif-
ferentiation in vivo [29,30]. Finally, recent evidence indi-
cates that monocyte-derived macrophages, peritoneal
macrophages, microglia and dendritic cells (DCs) obtain
anti-inflammatory characteristics following internaliza-
tion of myelin [12-14,31]. These studies clearly demon-
strate that macrophages, besides their apparent role in
neurodegeneration, may exert a neuroprotective influ-
ence on MS pathogenesis by clearance of myelin debris
and by altering their phenotype following myelin
internalization.
Perivascular macrophages, infiltrated macrophages and
microglia are ideally positioned to influence infiltrating
and infiltrated myelin-reactive lymphocytes. Indeed,
CNS reactivation of autoreactive lymphocytes by local
antigen presenting cells displaying myelin antigens is
thought to initiate and maintain the inflammatory cas-
cade observed in the brain of MS patients [3,4,32]. The
presence of brain antigen-containing phagocytes in sec-
ondary lymph nodes in MS and EAE further emphasizes
a possible crucial role of these cells in modulating the
immune response during MS and EAE pathogenesis
[33-35]. Phenotypical analysis of these macrophages
further revealed that in contrast to neuronal antigen
containing phagocytes, the majority of myelin-containing
APCs express anti-inflammatory mediators. How brain
antigens gain excess to CNS draining secondary lymph
nodes, either chemotactically in the context of phago-
cytes or as soluble products, remains to be clarified
[12,36,37].
In this study we investigated the capacity of myelin-
phagocytosing macrophages (mye-macrophages) to
influence lymphocyte proliferation. We show that mye-
macrophages inhibit TCR-triggered lymphocyte prolif-
eration in an antigen-independent manner. This process
is mediated by an enhanced nitric oxide (NO)
production. Furthermore, we demonstrate that myelin
delivery to popliteal lymph nodes of OVA-immunized
animals and uptake by primarily CD169
+ macrophages
reduces cognate antigen specific proliferation following
restimulation ex vivo. The elevated production of NO
detected in these lymph node cultures indicates that NO
may also mediate the immune suppressive effects in
vivo. In contrast, myelin delivery to popliteal lymph
nodes did increase lymphocyte reactivity in MBP-immu-
nized animals. Thus, mye-macrophages may play a sup-
pressive role in CNS-draining lymph nodes during MS
pathogenesis, depending on the nature of surrounding
lymphocytes. Collectively our data provide evidence that
myelin phagocytosis leads to an altered macrophage
function that modulates lymphocyte responses.
Methods
Animals
Female Lewis rats, 6-8 weeks of age, were purchased
from Harlan Netherlands B.V. (Horst, The Netherlands).
Animals were housed in the animal facility of the Bio-
medical Research Institute of Hasselt University. Experi-
ments were conducted in accordance with institutional
guidelines and approved by the local Ethical Committee
for Animal Experiments of Hasselt University.
Isolation of peritoneal rat macrophages
Three days prior to macrophage isolation, rats were
injected intraperitoneally with 3 ml 3% thioglycolate
(Sigma-Aldrich, Bornem, Belgium). Resident peritoneal
macrophages were obtained by peritoneal lavage using
10 ml of ice-cold PBS (Lonza, Vervier, Belgium) supple-
mented with 5 mM ethylenediamine tetraacetic acid
(EDTA; VWR, Leuven, Belgium). Peritoneal exudate
cells (PECs) were cultured for 2 hours in RPMI 1640
medium. After 2 hours incubation at 37°C with 5% CO2,
non-adherent cells were washed away. Remaining cells
were >95% macrophages [38].
Myelin phagocytosis
Myelin was purified from rat brain tissue by means of
density-gradient centrifugation, as described previously
[39]. Myelin protein concentration was determined by
using the BCA protein assay kit (Thermo Fisher Scienti-
fic, Erembodegem, Belgium). LPS content was deter-
mined using the Chromogenic Limulus Amebocyte
Lysate assay kit (Genscript Incorperation, Aachen, Ger-
many). Isolated myelin contained a neglectable amount
of endotoxin (1.8 × 10
-3 pg/μg myelin).
Isolated myelin was fluorescently labelled, according to
the method of Van der Laan et al. [11]. In short, 10 mg/
ml myelin was incubated with 12.5 μg/ml 1,1"-diotade-
cyl-3,3,3’,3’,-tetramethylindocarbocyanide perchlorate
(DiI; Sigma-Aldrich) for 30 min at 37°C. Next, a myelin
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described [39].
Immunization and in vivo myelin treatment
Lewis rats were injected subcutaneously with a 0.1 ml
suspension containing 250 μg/ml guinea pig myelin
basic protein (MBP) or ovalbumin (OVA), 2.5 mg/ml
H37RA heat-killed mycobacterium tuberculosis (Difco,
Detroit, USA) and 60 μl Complete Freunds adjuvant
(Sigma-Alldrich) in both hind paws. Subsequently ani-
mals were injected subcutaneously with PBS, 2.6 × 10
6
latex beads (0.8 μm mean particle size, Sigma-Alldrich),
75 μg/animal of isolated myelin or OVA (d-4, 0, 4 and 8
pre- and post-immunization). MBP-immunized rats
were weighted and scored daily according to the follow-
ing neurological scale: 0 = no neurological abnormal-
ities, 0.5 = partial loss of tail tonus, 1 = complete loss of
tail tonus, 2 = hind limb paresis, 3 = hind limb paralysis,
4 = moribund, 5 = death.
Generation of antigen-specific lymphocytes
MBP and OVA-specific lymphocytes were obtained 9
days post-immunization by bilateral isolation of the
inguinal and popliteal lymph nodes. Single-cell suspen-
sions of harvested lymph nodes were obtained by grind-
ing with a syringe plunger against a 70 μm cell strainer
(Bellco Glass Inc., Vineland, USA). To enrich for antigen
specific lymphocytes, lymph node cells were restimu-
lated, as described previously [40]. Briefly, lymph node
cells were resuspended in stimulation medium: RPMI
1640 medium (Invitrogen, Merelbeke, Belgium) supple-
mented with 50 U/ml penicillin (Invitrogen), 50 U/ml
streptomycin (Invitrogen), 20 μM 2-mercapto-ethanol
(Sigma-Alldrich), 1% sodium pyruvate (Invitrogen), 1%
MEM non-essential amino acids (Invitrogen), 2% deacti-
vated autologous serum and 33 μg/ml MBP. After 2
days, cells were washed and resuspended in RPMI 1640
medium supplemented with 50 U/ml penicillin, 50 U/ml
streptomycin, 20 μM 2-mercapto-ethanol, 10% fetal calf
serum (FCS, Hyclone, Erembodegem, Belgium) and 6,5%
supernatants of Concanavalin (ConA, Sigma-Alldrich)
stimulated spleen cells. Following 2 days, cells were
washed and resuspended in RPMI 1640 medium supple-
mented with 50 U/ml penicillin, 50 U/ml streptomycin,
20 μM 2-mercapto-ethanol and 10% fetal calf serum for
3 days.
CFSE-labeling of lymphocytes
A carboxyfluorescein diacetatesuccinimidyl ester (CFSE)
stock (10 mM in DMSO, Invitrogen, Merelbeke, Bel-
gium) was diluted in PBS (Biowhittaker™). Antigen-spe-
cific lymphocytes were resuspended in PBS
supplemented with 0.05% BSA and 4 μMC F S E( 2 0×
10
6 cells/ml) for 7 min at 37°C with 5% CO2. Cells were
washed and diluted in 0.5 ml culture medium for 30
min at 37°C with 5% CO2 to stabilize the CFSE-labeling.
In parallel, to determine macrophage viability following
a coculture with lymphocytes, macrophages were labeled
with CFSE to distinguish them from unlabeled
lymphocytes.
Coculture of macrophages with lymphocytes
Prior to coculture with CFSE labeled lymphocytes, iso-
lated macrophages were seeded in flat-bottem 96-well
plates (15 × 10
3 cells/well) in RPMI 1640 medium sup-
plemented with 50 U/ml, 50 U/ml streptomycin and
10% FCS, and treated with 100 μg/ml of isolated myelin
for three hours. Excess myelin was removed by washing
twice with RPMI 1640 medium at 37°C. Subsequently,
stimulation medium containing irradiated thymocytes
(15 × 10
4, 3000 rad), CFSE-labeled MBP- or OVA-speci-
fic lymphocytes (15 × 10
4) and respectively 10 μg/ml
MBP or 10 μg/ml OVA were added. Untreated macro-
phages were used as a control. To evaluate the involve-
ment of respectively NO, arginase, indoleamine 2,3-
dioxygenase (IDO) the phagocytosis process itself, direct
cell-cell contact and IFNg,1 . 5m MN
G-Monomethyl-L-
arginine (L-NMMA; VWR), 0.5 mM N
G-Hydroxy-L-
arginine (NOHA; VWR), 0.2 mM 1-Methyl-L-trypto-
phan (1-MT; Sigma Alldrich), latex beads (1:100), 100
μg/ml zymosan A (Sigma-Alldrich), transwell inserts
(0.4 μm pore size, Sigma-Aldrich) or 10 μg/ml anti-rat
IFNg (Preprotech, London, UK) were tested in the
coculture model.
Flow cytometry was used to assess proliferation and
cell death of lymphocytes and macrophages after a 4
day coculture. Here, cells were stained with PE-conju-
gated mouse-anti-rat CD3 (Immunosource, Erembode-
gem, Belgium) or CD11b (AbD Serotec, Düsseldorf,
Germany) and 7 aminoactinomycin D (7AAD, BD
Biosciences).
[
3H]Thymidine incorporation
Isolated lymph node cells (20 × 10
4) were cultured with
MBP (10 μg/ml), OVA (10 μg/ml) or myelin-oligoden-
drocyte glycoprotein (MOG, 20 μg/ml). Additionally,
100 μg/ml of isolated myelin was added in some experi-
ments. Following 48 hr, 1 μCi [
3H]thymidine (Amer-
sham, Buckinghamshire, UK) was added to the culture.
Next, cells were harvested with an automatic cell har-
vester (Pharmacia, Uppsala, Sweden) and uptake of
radioactivity was measured in a b-plate liquid scintilla-
tion counter (Wallac, Turku, Finland).
Nitrite formation
Coculture supernatants were collected and release of NO
was determined using the griess reagent system (Pro-
mega, Leuven, Belgium), following the manufacturer’s
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microplate reader at 550 nm (Biorad Benchmark).
Histology and immunohistochemistry
Snap-frozen brain and spinal cord material was cut in
respectively the coronal and sagittal plane with a Leica
CM1900UV cryostat (Leica Microsystems, Wetzlar, Ger-
many) to obtain 10 μm sections. The extent of demyeli-
nation and infiltration was determined by staining with
Luxol Fast Blue (LFB; Gurr BDH, Poole, England).
Briefly, aceton-fixed slides were incubated with LFB for
16 hr at 56°C, destained with 0.05% lithium carbonate,
and counterstained with cresyl violet (VWR). Analysis
was carried out using a Nikon eclipse 80i microscope
and NIS Elements BR 3.10 software (Nikon, Tokyo,
Japan).
DiI-labeled myelin migration to popliteal and inguinal
lymph nodes was determined by immunohistochemistry.
Popliteal and inguinal lymph nodes were snap-frozen
directly following isolation and cut into 10 μm sections.
Following fixation in respectively aceton for 10 min, sec-
tions and cells were blocked using 10% goat serum
(Millipore, Brussels, Belgium) in PBS. Subsequently, sec-
tions and cells were stained with mouse-anti-rat CD169
(1/250 in PBS; Abd Serotec), a marker for macrophages
in lymph nodes. As a secondary antibody Alexa fluor
488 F(ab’)2 fragment of goat-anti mouse was used (1/
500 in PBS; Invitrogen). Control staining was performed
by omitting the primary antibody. Nuclear staining was
performed using 4,6’-diamidino-2-phenylindole (DAPI;
Invitrogen) for 10 min. Autofluorescence was minima-
lized by using 0.1% Sudan Black in 70% ethanol.
Statistical analysis
Data were statistically analyzed using GraphPad Prism
for windows (version 4.03) and are reported as mean ±
SEM. D’Agostino and Pearson omnibus normality test
was used to test normal distribution. An analysis of var-
iances (ANOVA) or two-tailed unpaired student T-test
(with Welch’s correction if necessary) was used for nor-
mally distributed data sets. The Kruskal-Wallis or
Mann-Whitney analysis was used for data sets which
did not pass normality. *P < 0,05, **P < 0,01 and ***P <
0,001.
Results
Myelin-laden macrophages inhibit lymphocyte
proliferation
Initially we assessed the capacity of peritoneal macro-
phages to internalize myelin. By culturing macrophages
with different concentrations of DiI-labeled myelin for
divergent periods of time, it was demonstrated that mye-
lin is internalized in a time- and dose-dependent manner
(Figure 1a). Next, the most optimal macrophage/
lymphocyte coculture ratio was determined by using
untreated macrophages. At high macrophage/lymphocyte
ratio’s, lymphocytes demonstrated a reduced viability and
proliferation (Figure 1b and 1c). The decline of lympho-
cyte viability was absent at low macrophage/lymphocyte
ratio’s (<1/10). To observe differences in lymphocyte pro-
liferation following coculture with mye-macrophages,
subsequent experiments were conducted using a macro-
phage/lymphocyte ratio of 1/10.
To study whether mye-macrophages affect antigen-
specific lymphocyte proliferation in a different manner
compared to untreated macrophages, macrophages or
mye-macrophages were cocultured for 4d with MBP- or
OVA-reactive lymphocytes, irradiated thymocytes and
purified MBP or OVA. Here it was demonstrated that
mye-macrophages inhibit TCR-triggered lymphocyte
proliferation more pronounced than untreated macro-
phages (Figure 1d and 1e). This process was indepen-
dent of antigen-specificity, since both MBP and OVA-
reactive lymphocytes showed the same reduction in pro-
liferation. Proliferation differences were not due to an
altered viability of lymphocytes or mye-macrophages
(data not shown).
Inhibition of lymphocyte proliferation is independent of
the phagocytosis process or myelin-antigen presentation
To elucidate the mechanisms behind the increased inhi-
bition of lymphocyte proliferation by mye-macrophages,
we assessed whether the phagocytosis process as such is
responsible for the observed effects on lymphocyte pro-
liferation. For this purpose, macrophages were loaded
for 3 consecutive hours with latex beads or zymosan A
prior to coculture with lymphocytes. Macrophage treat-
ment with beads or zymosan significantly affected their
capacity to modulate lymphocyte proliferation compared
to control and myelin treated macrophages (Figure 2a),
indicating that the observed increased inhibition of lym-
phocyte proliferation relies on myelin-specific effects,
instead of being induced by the phagocytosis process
itself.
Like DCs, macrophages can act as messengers of
innate and adaptive immunity by presenting antigen in
context of MHC molecules. Mye-macrophages can
therefore be assumed to process endogenous myelin and
present it to myelin-reactive lymphocytes, possibly influ-
encing reactivity of these lymphocytes. To determine
whether the observed immune suppressive effects are
dependent on antigen presentation, untreated macro-
phages and mye-macrophages were cocultured with
MBP-reactive lymphocytes in the absence of MBP and
irradiated thymocytes. Mye-macrophages did not affect
lymphocyte proliferation (Figure 2b), suggesting that, at
a macrophage/lymphocyte ratio of 1/10, mye-macro-
phages do not influence the proliferation of MBP-
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observed equal inhibition of proliferation of both MBP
and OVA-reactive lymphocyte by mye-macrophages.
Lipid components of myelin, like cholesterol and ara-
chidonic acid-containing phosphatidylcholine, have been
reported to directly inhibit proliferation of ConA stimu-
lated lymphocytes [41,42]. Accordingly, we assessed
whether isolated myelin has a direct effect on lympho-
cyte proliferation. By culturing lymphocytes with
increasing concentrations of isolated myelin, in the
absence of macrophages, it was established that myelin
itself, even at high concentrations, had no significant
influence on lymphocyte reactivity (data not shown).
Together, these data indicate that direct effects of
myelin on lymphocyte proliferation, myelin-antigen
presentation and the phagocytosis process itself are not
responsible for the observed effects on lymphocyte
proliferation.
Macrophages inhibit lymphocyte proliferation by the
production of nitric oxide
Macrophages have been reported to inhibit lymphocyte
proliferation in vitro by mechanisms involving inducible
nitric oxide synthase (iNOS), arginase I or IDO [43-55].
By administrating either an inhibitor of NOS (L-
NMMA), arginase (NOR-NOHA) or IDO (1-MT) to the
culture, the involvement of these enzymes was evalu-
ated. Here we demonstrated that an increased activity of
both IDO and arginase did not account for the
increased inhibition of lymphocyte proliferation by mye-
Figure 1 Myelin-phagocytosing macrophages inhibit TCR-triggered lymphocyte proliferation in an antigen-independent manner.( a )
Mean DiI-flourescence following treatment of macrophages with divergent concentrations of myelin (10 and 50 μg/ml) for several periods of
time (1 hr; white bars, 2 hr; black bars or 3 hr; grey bars). The dotted line represents untreated macrophages. Data represent the mean of two
independent experiments. (b, c) Lymphocyte proliferation and viability following a 4d coculture with irradiated thymocytes, purified MBP and
different concentrations of macrophages. The relative proliferation and viability is defined as the percentage of proliferating or viable cells in
experimental cultures divided by values in control lymphocyte cultures without macrophages (dotted line). Data represent the mean of three
independent experiments. (d, e) Proliferation of MBP or OVA-reactive lymphocytes following a 4d coculture with irradiated thymocytes,
macrophages or mye-macrophages (macrophage/lymphocyte ratio 1/10) and respectively purified MBP or OVA. Data represent the mean of six
(d) and four (e) independent experiments. Dotted line represents the proliferation of control lymphocyte cultures without macrophages. Ma:
Macrophages.
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lymphocyte proliferation following coculture with untreated, myelin-, zymosan- (Zym) or latex bead-treated macrophages. The relative
proliferation is defined as the percentage of proliferating cells in experimental cultures divided by values in control lymphocyte cultures without
macrophages (dotted line). Data represent the mean of two independent experiments. (b) To determine the capacity of mye-macrophages to
present myelin antigens, MBP-reactive lymphocytes were cocultured with macrophages or mye-macrophages (ratio 1/10) in the absence of
thymocytes and MBP. Data represent the mean of two independent experiments. (c) The role of respectively IDO, arginase and NO in the
observed inhibition of proliferation, macrophage coculture (black bars) and mye-macrophage coculture (white bars), was determined by addition
of an IDO inhibitor (1-MT), an arginase inhibitor (Nor-NOHA) and an iNOS inhibitor (L-NMMA). Dotted line represents the proliferation of control
lymphocyte cultures without macrophages. Data represent four independent experiments. (d) Relative NO concentration in supernatants
following a 4d coculture with MBP-reactive lymphocytes. Dotted line represents the NO production of control lymphocyte cultures without
macrophages. Data represent the mean of 4 independent experiments. (e) Comparison of lymphocyte proliferation following coculture with
untreated and myelin-treated macrophages using transwell inserts. Dotted line represents the proliferation of control lymphocyte cultures
without macrophages. Data represent the mean of two independent experiments. (f) Ex vivo proliferation (black bar) and viability (white bar) of
lymph node cells following a coculture with MBP and myelin. Proliferation was compared to cultures in which no myelin was added. Lymph
nodes were isolated 9d-post MBP-immunization. Data represent three independent experiments. Ma: Macrophages, LN: Lymph node, TW:
transwell inserts.
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L-NMMA completely abrogated the inhibition of lym-
phocyte proliferation by both macrophages and mye-
macrophages. Yet again, cocultures of both OVA and
MBP-reactive lymphocytes were affected equally (data
not shown). The importance of NO was further deli-
neated by assessment of NO levels in the coculture
supernatant of MBP-reactive lymphocytes. In contrast to
cocultures of lymphocytes with latex beads or zymosan
treated macrophages, a significantly increased concen-
tration of NO was observed in the supernatants derived
from cocultures with mye-macrophages, when compared
to untreated macrophages (Figure 2d). This increased
NO production by macrophages following myelin inter-
nalization was absent in monocultures (data not shown),
indicating that the observed increased concentration of
NO in the coculture with mye-macrophages was
induced by lymphocytes. Lymphocyte-derived IFNg has
previously been described to induce NO production in
macrophages [56]. However, in our coculture model no
increase in IFNg in the supernatants of cocultures with
mye-macrophages compared to untreated macrophages
was found (data not shown). Correspondingly, IFNg
neutralization did neither abrogate the increased inhibi-
tion of proliferation by mye-macrophages or decrease
the NO production in cocultures (data not shown).
Nonetheless, when transwell inserts were used to restrict
direct cell-cell contact, lymphocyte proliferation in
cocultures of both untreated or myelin-treated
approached control values (Figure 2e), indicating a role
for direct cell-cell contact in the induction of NO.
Noteworthy, when lymph node cells, isolated 9 days
post-immunization, were exposed directly to MBP and
myelin, an even more pronounced myelin-mediated
inhibition of lymphocyte proliferation was observed (Fig-
ure 2f). The latter indicates that local lymph node pha-
gocytes show a similar immune suppressive response as
peritoneal macrophages following myelin ingestion. Dif-
ferences detected in proliferation were not due to an
altered viability of lymphocytes (Figure 2f).
Myelin modulates lymph node proliferation in vivo
Since we established that myelin internalization by
macrophages alters their capacity to modulate T cell
proliferation in vitro, we assessed the in vivo suppressive
capacity of mye-macrophages. First, to determine
whether subcutaneous injected myelin reaches the
draining lymph node and is taken up by macrophages,
we injected DiI-labeled myelin in the footpad of healthy
animals. A notable migration of myelin towards popli-
teal lymph nodes was observed (Figure 3a). Immunohis-
tochemical analysis further revealed that myelin was
contained primarily in CD169
+ macrophages located at
the border of the medulla and in the subcapsular sinus
(Figure 3b).
Next, OVA-immunized animals were treated subcuta-
neously in the footpad with myelin (d-4, 0, 4, 8 pre/
post-immunization). Recall stimulation in vitro, 9d post-
immunization, revealed a reduced cognate antigen speci-
fic proliferation in animals treated with myelin (Figure
4a). Interestingly, LPS-stimulated lymph node cultures
from myelin-treated animals demonstrated an increased
NO production (Figure 4b). These results demonstrate
that myelin is capable of suppressing antigen-specific
proliferation in vivo and suggest that an increased NO
production by these cells is responsible for this effect.
Figure 3 Myelin-mediated inhibition of lymph node
proliferation and myelin migration to CD169
+ macrophages in
popliteal lymph nodes. (a) DiI-labeled myelin was injected
subcutaneously in the footpad of healthy animals. DiI-flourescene
was determined 4d post-injection by flow cytometry. One
experiment is shown. (b) Immunohistochemical staining of popliteal
lymph nodes 4d post-injection of DiI-labeled myelin. Sections were
additionally stained with CD169 and DAPI. pMa: Peritoneal
macrophages, LN: Lymph node.
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nized animals revealed an increased reactivity towards
MBP and MOG following myelin treatment (Figure 5a).
Moreover, myelin-treated animals demonstrated an ear-
lier onset of paralysis and a more severe neurological
score at the peak of disease (Figure 5b). In concordance,
a LFB/cresyl violet staining of brain and spinal cord sec-
tions demonstrated increased cellular infiltrates and the
presence of demyelinated areas in myelin-treated ani-
mals (Figure 5c). Noteworthy, when MBP-immunized
animals were treated with latex beads no overt effect on
disease score and onset was found (data not shown),
indicating that the aggravated disease score following
myelin treatment is myelin-specific.
To exclude the possibility that in the restricted area of
the lymph node the availability of OVA in OVA-immu-
nized animals is altered by the additional presence of
myelin proteins, hereby reducing OVA-specific prolifera-
tion, MBP-immunized animals were treated subcuta-
neously with OVA. As expected, an increased reactivity
towards OVA was observed in isolated lymph node cells
(Figure 6a). However, MBP-specific proliferation was
unchanged (Figure 6b), demonstrating that the observed
myelin-mediated inhibition of proliferation of lymph
nodes cultures from OVA-immunized is independent of
a reduced availability of OVA by myelin proteins.
These results indicate that mye-macrophages have a
dual influence on proliferation, depending on the nature
of surrounding lymphocytes. On one hand they aggra-
vate autoimmunity by activating myelin-reactive lym-
phocytes and on the other hand they have the capacity
to suppress lymphocyte activation by the secretion of
NO.
Discussion
In this study we have established that macrophages that
have phagocytosed myelin modulate the proliferation of
autoreactive T cells. The observed inhibition of TCR-
triggered lymphocyte proliferation by mye-macrophages
was antigen-independent, as both OVA- and MBP-reac-
tive lymphocytes show an identical reduction in prolif-
eration following coculture with mye-macrophages in
vitro. Additionally, when in vivo primed lymph node
cultures were restimulated directly in vitro in the pre-
sence of myelin, an even more pronounced immune
suppression was observed. These results indicate that
both macrophages and lymph node phagocytes obtain
immune suppressive properties following myelin
internalization.
Macrophages may inhibit proliferation of lymphocytes
in various manners, including IDO-mediated depletion
of tryptophan, arginase-mediated lowering of L-arginine
and lymphocyte CD3ζ expression, and NO-mediated
reduction of tyrosine residue phosphorylation in the
Jak3/STAT5 pathway and inhibition of caspase activity
[43-52]. We demonstrate that the non-selective iNOS
inhibitor L-NMMA completely reversed the observed
inhibition of proliferation by both control and mye-
macrophages while the other pathways were not
involved. In line with this, an increased concentration of
NO was demonstrated in the coculture supernatant of
mye-macrophages, explaining the observed inhibition of
lymphocyte proliferation by mye-macrophages.
Abrogation of direct cell-cell contact restored lympho-
cyte proliferation in our cocultures. This finding,
together with the observed role of NO in the inhibition
of lymphocyte proliferation, suggests that direct contact
between both cell types is a necessary prerequisite for
stimulating NO-mediated inhibition of lymphocyte pro-
liferation by macrophages. On the other hand, NO
might, due to extreme short half-life, not reach lympho-
cytes when direct contact is restricted. Future studies
should therefore determine the mechanism behind the
macrophage- and mye-macrophage-mediated inhibition
of lymphocyte proliferation in our cocultures. Although
lymphocyte-derived IFNg is described to induce NO
production by macrophages, we were unable to demon-
strate a role for lymphocyte-produced IFNg in the
observed inhibition of lymphocyte proliferation [56].
As we demonstrated an increased, NO-mediated inhi-
bition of lymphocyte proliferation by mye-macrophages
in vitro, myelin-rich phagocytes in secondary lymph
nodes might fulfill an identical suppressive role in vivo.
CD169
+ macrophages in lymph nodes are described to
b ep r i m a r i l yi n v o l v e di nu p t a k ea n dr e l a yo fv i r a l
Figure 4 Myelin inhibits lymphocyte proliferation in OVA-
immunized animals. (a) OVA-immunized animals (N = 7) were
treated with myelin at day -4, 0, 4 and 8 (or left untreated). Nine
days post-immunization, OVA-reactivity of isolated lymph node
cultures was assessed. Non-stimulated cultures were used as control.
Data represent the mean of seven independent experiments. (b) NO
production by LPS-stimulated popliteal lymph node cultures 9d
post-immunization. Lymph node cultures were stimulated with LPS
for 18 hr after which NO production in the supernatant was
determined. Data represent the mean of seven independent
experiments. Pop. LN: Popliteal lymph node.
Bogie et al. Journal of Neuroinflammation 2011, 8:85
http://www.jneuroinflammation.com/content/8/1/85
Page 8 of 13Figure 5 MBP-immunized animals demonstrate an aggravated disease course following myelin treatment. (a) MBP-immunized animals
were treated with isolated myelin at day -4, 0, 4 and 8 (or left untreated). Ten days post-immunization popliteal lymph node cultures were
isolated and MBP (white bars) and MOG (black bars) reactivity was assessed. Non-stimulated cultures were used as control. Data represent the
mean of two independent experiments. (b) Neurological score of control (N = 5) and myelin-treated (N = 5), immunized animals was assessed
daily. Due to severity of paralysis, myelin-treated animals were sacrificed at d10. (c) LFB/cresyl violet staining of spinal cord (left) and brain tissue
(right) of myelin-treated animals at day 10. Arrows depict demyelinated regions. One experiment is shown. Pop. LN: Popliteal lymph node.
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Page 9 of 13particles and immune complexes, and activation of folli-
cular B lymphocytes [57-60]. We demonstrate that a
subcutaneous injection of myelin in the footpad results
in a notable migration of myelin towards CD169
+
medullary and subcapsular sinus (SCS) macrophages in
popliteal lymph nodes. Given the abundance of lipids in
myelin, these results are in line with a recent report
showing active phagocytosis of lipid-coated silica parti-
cles by SCS macrophages [61].
To explore the possible immune suppressive proper-
ties of mye-macrophages in vivo, OVA-immunized ani-
mals were treated subcutaneously in the footpad with
myelin. Restimulated popliteal lymph nodes of myelin-
treated animals display reduced OVA-induced prolifera-
tion compared to lymphocytes derived from untreated
OVA-immunized animals. This effect is independent of
interference of myelin proteins on OVA antigen presen-
tation, as lymph node cultures of MBP-immunized ani-
mals treated subcutaneously with OVA did not reduce
MBP reactivity. These results demonstrate that mye-
macrophages suppress lymphocyte proliferation in vivo.
In contrast, lymph node cultures derived from MBP-
immunized animals that were treated with myelin
showed an enhanced proliferative capacity. Although we
demonstrated that mye-macrophages are unable to
increase proliferation of MBP-reactive lymphocytes in
vitro, the presence of other myelin-rich antigen-present-
ing cells, like migrated langerhans cells and local lymph
node DCs, might explain the increased reactivity against
MBP and MOG. Furthermore, B cells have been
described to capture antigen-containing immune com-
plexes from SCS macrophages processes and migrate to
the T cell zone to influence antigen presentation
[57,60]. Finally, the discrepancy in literature regarding
the skewing of macrophages following myelin internali-
zation suggests that myelin can have divergent effects
on macrophage polarization and its APC-like or
immune suppressive properties, which may depend on
the macrophage origin and local environmental stimuli.
Likewise, the nature of surrounding lymphocytes, for
example being myelin-protein, non-myelin or myelin-
lipid specific, might determi n ew h e t h e rt h ep r e s e n c eo f
mye-macrophages results in stimulation or suppression
of lymphocyte activity. Future studies should therefore
determine whether lymphocytes surrounding mye-
macrophages in CNS draining lymph nodes recognize
antigen presented by these cells and are hereby
activated.
Interestingly, we demonstrated an increased capacity of
lymph nodes cells from myelin treated, OVA-immunized
animals to produce NO following LPS stimulation. These
results indicate a direct role of macrophage-produced
NO in the observed decrease in OVA reactivity in mye-
lin-treated animals, as observed in vitro. The importance
of NO in the control of inflammation in EAE is sup-
ported by studies showing an aggravation or inability to
recover following treatment with an iNOS inhibitor in
respectively the induction or the remission phase of EAE
[62,63]. Likewise, treatment with the NO-donor SIN-1
during the induction phase of EAE ameliorated EAE,
which was correlated with a reduced immune cell infil-
tration and antigen-induced proliferation [64]. Finally,
EAE insusceptibility in rat strains like the Piebald Virol
Glaxo and the Brown Norway strain was correlated with
an increased production of immune suppressive NO fol-
lowing immunization [65,66]. These results demonstrate
that NO displays a disease-mitigating role in EAE by
inhibiting lymphocyte proliferation. Based on these and
our findings, we suggest that mye-macrophages in the
perivascular space and CNS-draining lymph nodes can
fulfill a suppressive role in MS by producing NO, hereby
silencing autoreactive lymphocytes.
It is unclear which myelin components are responsible
for the observed immune suppressive effects. To date,
despite the abundance of lipids in myelin, most studies
have mainly focused on the role of myelin proteins in
neurodegenerative diseases. Interestingly, several lipids
present in myelin have been reported to alter macro-
phage signaling and transcription. Intracellular, lipid
sensors like LXR and PPAR, which are respectively acti-
vated by cholesterol derivates and non-esterified fatty
acids, have recently been described as key regulators of
lipid metabolism and inflammation, and may be acti-
vated following myelin internalization [67-69]. Similarly,
individual lipids present in myelin can alter the macro-
phage or microglial response by binding to specific
receptors and activating or blocking signalling cascades
pivotal in inflammation [70-73].
Macrophages can adopt divergent phenotypes based
on specific stimuli in their microenvironment [74-77].
Figure 6 OVA does not influence lymphocyte reactivity to MBP
in MBP-immunized animals. (a, b) MBP-immunized animals (N =
4) were treated with OVA at day -4, 0, 4 and 8 (or left untreated).
Nine days post-immunization, OVA- (a) and MBP (b) reactivity of
isolated lymph node cultures was assessed. Non-stimulated cultures
were used as control. Data represent the mean of four independent
experiments. Pop. LN: Popliteal lymph node.
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Page 10 of 13Moreover, mye-macrophages have been described to
display divergent phenotypes depending on the location
in the lesion, suggesting that they are likely to exert
diverse functions depending on their micro-location
[12]. By using thioglycolate-elicited PECs, as a represen-
tative model for infiltrating monocytes in EAE and MS,
we established that myelin internalization results in an
altered macrophage function, characterized by an
increased production of NO [78]. These mye-macro-
phages may have dual effects during MS pathogenesis.
Whereas NO production by mye-macrophages can
negatively influence neuronal integrity and block axonal
conduction locally in the brain parenchyma, we show
that NO also suppresses lymphocyte proliferation. Thus,
depending on the surrounding cells, mye-macrophages
can be involved in either limiting or promoting autoim-
mune-mediated demyelination.
Conclusion
We demonstrate that myelin phagocytosis leads to an
altered macrophage function that inhibits lymphocyte
proliferation. The observed immune suppression was
mediated by an increased production of NO by mye-
macrophages. Additionally, we establish that mye-
macrophages fulfill an ambiguous role in vivo.O no n e
hand mye-macrophages aggravate autoimmunity by acti-
vating myelin-reactive lymphocytes in secondary lymph
nodes and on the other hand they suppress lymphocyte
reactivity by producing NO.
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